IX
Instrumentation, controls & outage services
Every reactor — new or restarted — buys radiation detection, I&C, dosimetry and outage services from a thin specialist bench.
Chokepoint IX is the least glamorous and most reliable layer of the nuclear buildout: every reactor — newbuild AP1000, restarted Palisades or Crane, uprated PWR, or first-of-a-kind SMR — must buy radiation detection, dosimetry, safety-grade instrumentation & control (I&C), and outage/field services from a thin specialist bench before it can legally operate. Unlike the SMR developers two chokepoints over, these names ship revenue today and bill against an installed base of ~440 reactors worldwide that does not care whether any new design ever reaches criticality.
Who owns it
The purest pure-play is Mirion (NYSE: MIR), which posted FY2025 revenue of $925.4M and $227.9M adjusted EBITDA on radiation detection, dosimetry, and nuclear I&C. Mirion booked over $1B of orders in 2025 and exited Q1 2026 with $1.1B backlog, 62% of it tied to the nuclear power end-market. It bought its way deeper into the choke: Certrec for $81M (regulatory compliance, July 2025) and Paragon Energy Solutions for $585M (safety-related nuclear components, closed Dec 1 2025). Curtiss-Wright (NYSE: CW) is the dual-hat name: sole-source AP1000 reactor coolant pumps plus, via the $200M Ultra Energy acquisition (closed Jan 2025), reactor protection systems, neutron monitoring, and radiation monitoring instrumentation. BWX Technologies (NYSE: BWXT) owns the outage/field-services and components leg, amplified by the Kinectrics acquisition, and ended 2025 with $7.3B total backlog (+50% y/y) and $1.7B commercial backlog (+85%). Fluor (NYSE: FLR) sits at the EPC edge.
What breaks it
The constraint is qualification, not capacity. Safety I&C must clear NRC review; the relevant proof point is digital-I&C licensing under the NRC's new interim staff guidance — Framatome won a December 2025 contract to upgrade digital control systems at the Columbia Generating Station — but Framatome is unlisted (EDF ~80.5%/MHI 19.5%), so there is no clean ticker for that work. Pre-qualified platforms (Curtiss-Wright/Ultra's NRC-accepted reactor protection systems, Mirion's installed detection base) are moats precisely because a new entrant needs years and a docket to displace them. The risk is timing: restart and newbuild schedules slip (Palisades has repeatedly), and the biggest single CW catalyst — an AP1000 reactor-coolant-pump order — is explicitly excluded from 2026 guidance pending customer decisions.
What forces the reprice
The catalyst tape is the restart/uprate calendar and the DOE pilot program racing a July 4 2026 criticality deadline. Each restart (Palisades targeting 2026, Crane 2027) and each SMR moving from design to prototype pulls forward detection, dosimetry, and I&C orders — Mirion already logged a $35M SMR order in April 2026. An actual AP1000 RCP award would be pure upside to CW guidance.
Be honest about size and earliness
This chokepoint is real revenue, not a call option — but it is small and the multiples already discount the renaissance. Mirion's entire company is under $1B of revenue, and nuclear is a segment of it; dosimetry is stable but a low-growth annuity, not a hypergrowth line. For CW, BWXT, and FLR, nuclear I&C/services is a fraction of diversified defense-and-industrial businesses — buying CW or BWXT is buying naval propulsion and defense first, nuclear instrumentation second. Fluor is the sharpest honesty case: it is the lead EPC partner on NuScale's RoPower Romania project (FID Feb 2026), but it sold its entire NuScale equity stake for ~$2.43B of proceeds through April 2026, so FLR is now an EPC-services bet, not an SMR equity bet, and its nuclear backlog is a thin slice of a $25.5B book. None of this is advice; it is structure. The names that ship instruments today are the only ones in nuclear that already have an orderbook to point to — which is the entire reason to separate them from the pre-revenue developers.
Who owns the choke
BWX Technologies, Inc.
The most diversified US nuclear-components name: sole US naval-reactor fuel supplier (NFS, Erwin TN), TRISO fuel at Lynchburg, and — through its Cambridge, Ontario commercial-nuclear operations — heavy-walled pressure vessels and reactor components (including a GE Hitachi BWRX-300 RPV award). One of six DOE HALEU-deconversion IDIQ awardees. FY2026 guidance raised above $3.75B; backlog ~$8.65B, up 77% YoY.
- Bull
- The most diversified US nuclear-components name spans naval fuel, TRISO, pressure vessels, HALEU deconversion and microreactors, with backlog up 77% to ~$8.65B funding the buildout.
- Bear
- Much of the franchise rides on government and naval programs, leaving commercial-reactor forging and SMR revenue dependent on award timing and customer ramp execution.
[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]
Curtiss-Wright Corporation
Curtiss-Wright completed its $200M acquisition of Ultra Energy in January 2025, adding reactor protection systems, neutron monitoring and radiation monitoring instrumentation to its existing sole-source AP1000 reactor coolant pump franchise. Q1 2026 sales rose 13% to $914M with an order book near $4.3B; management says an AP1000 RCP order is still expected this year but is excluded from 2026 guidance.
- Bull
- Curtiss-Wright pairs its sole-source AP1000 reactor coolant pump franchise with newly acquired Ultra Energy instrumentation, positioning it across two thin chokepoints as the order book nears $4.3B.
- Bear
- The expected AP1000 RCP order is excluded from 2026 guidance, so the central commercial-nuclear catalyst could slip and disappoint a richly priced name.
Fluor Corporation
Fluor is the lead EPC partner for NuScale's six-module RoPower SMR project in Romania, which reached final investment decision in February 2026. Fluor monetized its entire NuScale stake for roughly $2.43B of proceeds between September 2025 and April 2026 (vs ~$570M invested); total company backlog stood at $25.5B at end-2025.
- Bull
- Fluor is lead EPC on NuScale's six-module RoPower SMR that reached FID, and it monetized its NuScale stake for ~$2.43B against ~$570M invested, a clean realized win.
- Bear
- Now that the NuScale stake is sold, nuclear is a small slice of a $25.5B diversified EPC backlog, leaving little direct SMR equity upside.
Mirion Technologies, Inc.
Mirion reported FY2025 revenue of $925.4M and adjusted EBITDA of $227.9M (24.6% margin), booked over $1B of orders in 2025, and exited Q1 2026 with $1.1B backlog (62% nuclear-power end-market). It acquired Certrec ($81M, July 2025) and Paragon Energy Solutions ($585M all-cash, closed Dec 1 2025) to add safety-related nuclear components and regulatory-compliance software.
- Bull
- Mirion's $1.1B backlog is 62% nuclear-power, with $925M revenue, 24.6% EBITDA margins and the Certrec and Paragon deals deepening its hold on the thin instrumentation-and-services bench.
- Bear
- A growth profile built partly on acquisitions carries integration risk, and the radiation-detection thesis depends on new-build and restart volumes actually materializing on schedule.
Catalyst calendar
- 2026-07-04DOE pilot-program criticality deadline for first advanced reactorshighThe presidential criticality deadline forces pilot reactors toward fueling and startup, each pulling forward orders for radiation detection, dosimetry and safety I&C from the specialist bench.
- 2026-07-30Mirion Q2 2026 earningsmediumFirst read on nuclear-power backlog conversion after Paragon/Certrec integration and the April $35M SMR order — the cleanest pure-play print on detection/dosimetry/I&C demand.
- 2026-08-03BWX Technologies Q2 2026 earningsmediumTests whether commercial-nuclear field-services and components backlog (Kinectrics-driven, $1.7B) keeps compounding off outage and life-extension timing.
- 2026-08-05Curtiss-Wright Q2 2026 earningsmediumWatch for any AP1000 reactor-coolant-pump order (excluded from 2026 guidance) and for Ultra Energy nuclear-instrumentation pull-through as SMR designs move from design to prototype.